Immune Monitoring and Tacrolimus (Tac) Withdrawal in Low Risk Recipients of Kidney Transplants - Results of CTOT09.
Richard N. Formica(Yale University), Donald E. Hricik(University Hospitals of Cleveland), Peter Nickerson(Shared Services Canada), Ian W. Gibson(University of Manitoba), Emilio D. Poggio(Cleveland Clinic), Robert L. Fairchild(Cleveland Clinic), Suphamai Bunnapradist(University of California, Los Angeles), Kathryn Tinckam(Brigham and Women's Hospital), David Iklé(Rho (United States)), O. Graber(Museum of Fine Arts, Houston), Peter S. Heeger(Cedars-Sinai Medical Center), David N. Rush(Manitoba Health), Brian Armstrong(Rho (United States)), Milagros Samaniego(Henry Ford Health System), Nancy D. Bridges(National Institute of Allergy and Infectious Diseases)
Cited by 4
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k
KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update
|American Journal of Kidney Diseases|2015|1.3k
Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection
|American Journal of Transplantation|2003|1.1k